These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 16100796)
21. Appeals court approves laetrile use by terminally ill cancer patients. Am Med News; 1978 Jul; 21(28):1, 10. PubMed ID: 10308640 [No Abstract] [Full Text] [Related]
22. Laetrile: what we know and what we do about it. Jones GT; Abramson N J Fla Med Assoc; 1979 May; 66(5):548-52. PubMed ID: 379271 [No Abstract] [Full Text] [Related]
23. The Garden State just got greener: New Jersey is the fourteenth state in the nation to legalize medical marijuana. Brown M Seton Hall Law Rev; 2011; 41(4):1519-67. PubMed ID: 22368811 [No Abstract] [Full Text] [Related]
24. Reading our lips: the history of lipstick regulation in Western seats of power. Schaffer SE Food Drug Law J; 2007; 62(1):165-225. PubMed ID: 17444030 [No Abstract] [Full Text] [Related]
25. [Laetrile, is it or is it not a miracle drug against cancer?]. Prins ME; Mulder JH Ned Tijdschr Geneeskd; 1979 Jul; 123(27):1141-4. PubMed ID: 460466 [No Abstract] [Full Text] [Related]
26. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh. Basile EM; Tolomeo D; Gluck E Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744 [TBL] [Abstract][Full Text] [Related]
27. Laetrile: the battle moves into the courtroom. Schwartz RL Am Bar Assoc J; 1979 Feb; 65():224-8. PubMed ID: 11661617 [No Abstract] [Full Text] [Related]
28. Laetrile: quacks and freedom. Br Med J; 1977 Jan; 1(6052):3-4. PubMed ID: 188511 [No Abstract] [Full Text] [Related]
29. Freedom of choice in medical treatment: reconsidering the efficacy requirement of the FDCA. Clinite BJ Loyola Univ Chic Law J; 1977; 9(1):205-26. PubMed ID: 11661566 [No Abstract] [Full Text] [Related]
30. People v. Privitera: the right to prescribe and use Laetrile. Brandt EK West State Univ Law Rev; 1978; 5(2):201-229. PubMed ID: 11661590 [No Abstract] [Full Text] [Related]
31. New drug development. Taylor WJ Int Z Klin Pharmakol Ther Toxikol; 1969 Apr; 2(2):105-13. PubMed ID: 4895441 [No Abstract] [Full Text] [Related]
33. The judicial dilemma of Laetrile and a possible solution. Pendergast WR Mercer Law Rev; 1979; 30(3):573-84. PubMed ID: 11661827 [No Abstract] [Full Text] [Related]
35. Understanding the Rewards of Successful Drug Development - Thinking Inside the Box. Khullar D; Ohn JA; Trusheim M; Bach PB N Engl J Med; 2020 Jan; 382(5):473-480. PubMed ID: 31995697 [No Abstract] [Full Text] [Related]
36. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies. Dudzinski DM Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771 [No Abstract] [Full Text] [Related]
37. Regulating Homeopathic Products - A Century of Dilute Interest. Podolsky SH; Kesselheim AS N Engl J Med; 2016 Jan; 374(3):201-3. PubMed ID: 26789866 [TBL] [Abstract][Full Text] [Related]
38. Drug development history, "overview," and what are GCPs? Heilman RD Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867 [TBL] [Abstract][Full Text] [Related]
40. Fifty Years of Expert Advice - Pharmaceutical Regulation and the Legacy of the Drug Efficacy Study. Schwartz JL N Engl J Med; 2016 Nov; 375(21):2015-2017. PubMed ID: 27959733 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]